Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham’s Emerging Companies & Growth Practice, sits down with BridgeBio’s Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian Stephenson. Since 2015, BridgeBio, a commercial-stage biopharmaceutical, has maintained a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. Latham has been involved with BridgeBio since its inception, representing BridgeBio on multiple fronts, including recently the company’s US$1.25 billion cross-border capital financing, one of the largest private capital financings in life sciences in the last five years, and one of the largest combined senior debt and royalty transactions in the last decade.

In a wide-ranging conversation, Haim, Neil, and Brian discuss BridgeBio’s novel rise from startup to unicorn, how the company’s portfolio has increasingly diversified and adjusted, and why BridgeBio represents the right approach to establishing enterprise and patient value in the genetics — and broader biotech — space. They also reflect on balancing patient impact with value creation, their anticipation of faster approval timelines in a new presidential administration, and the lessons learned from the evolution of BridgeBio’s legal structure, as well as which fast food is near and dear to their stomachs, and who was the biggest nerd in grad school.

Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.